CHA Bio

CHA Biotech is a prominent South Korean biotechnology company at the forefront of cell and gene therapy development. Operating as a key subsidiary of the CHA Bio Group, the company integrates clinical research with a global healthcare network to develop regenerative medicines and oncology treatments. Its core competencies include stem cell isolation and expansion, as well as the development of highly potent natural killer (NK) cell therapies. Beyond its internal pipeline, CHA Biotech provides comprehensive CDMO services through its global infrastructure, including Matica Biotechnology in the United States. The company's diverse portfolio targets high-unmet-need conditions such as Alzheimer's disease, stroke, and various solid tumors.